Head-To-Head Comparison: ViewRay (VRAY) and Presbia (LENS)
ViewRay (NASDAQ: VRAY) and Presbia (NASDAQ:LENS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
Insider and Institutional Ownership
47.0% of ViewRay shares are owned by institutional investors. Comparatively, 16.5% of Presbia shares are owned by institutional investors. 62.8% of ViewRay shares are owned by company insiders. Comparatively, 74.7% of Presbia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares ViewRay and Presbia’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|ViewRay||$22.24 million||28.63||-$50.63 million||($1.09)||-8.66|
Presbia has higher revenue, but lower earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Presbia, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for ViewRay and Presbia, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ViewRay presently has a consensus target price of $10.60, suggesting a potential upside of 12.29%. Presbia has a consensus target price of $11.33, suggesting a potential upside of 236.30%. Given Presbia’s higher probable upside, analysts clearly believe Presbia is more favorable than ViewRay.
This table compares ViewRay and Presbia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ViewRay beats Presbia on 6 of the 11 factors compared between the two stocks.
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.
Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.